Last reviewed: July 9, 2026

Last updated: July 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy (semaglutide) has reshaped weight loss treatment, but strict brand-name criteria and supply challenges leave many patients unable to access it. Semaglutide works by slowing stomach emptying and signaling fullness to the brain through GLP-1 receptors, reducing appetite by up to 35% in clinical trials. PlexusDx offers compounded semaglutide injections from licensed 503A pharmacies, making this medication accessible without insurance hurdles or waitlists.

Standard Wegovy Qualification Requirements

Wegovy eligibility centers on three clinical benchmarks: a body mass index (BMI) of 30 or higher, a BMI of 27 or higher with at least one weight-related condition (hypertension, diabetes, heart disease), or previous failure with other weight-loss approaches. The brand requires a documented medical history and prescriber evaluation before dispensing. Many patients meet these criteria but face 6–12 week shortages, high out-of-pocket costs ($1,400–$1,500 per month), or insurance denials based on formulary restrictions.

Medical clearance also demands screening for personal or family history of thyroid cancer, multiple endocrine neoplasia type 2, or severe pancreatitis, as semaglutide carries a black-box warning for medullary thyroid carcinoma in animal models. Your prescriber will order baseline labs, blood pressure checks, and sometimes imaging before approval. This thorough vetting protects safety but extends the timeline and adds out-of-pocket diagnostic costs in uninsured patients.

How BMI and Weight-Related Conditions Determine Eligibility

BMI remains the primary gatekeeper for semaglutide therapy. A BMI of 30 or higher qualifies most patients; a BMI of 27–29.9 paired with type 2 diabetes, hypertension, or cardiovascular disease also meets FDA criteria for the branded drug. BMI is calculated as weight (pounds) divided by height (inches) squared, multiplied by 703. For example, a 200-pound person who is 5'8" has a BMI of 30.4, crossing the eligibility threshold.

Weight-related comorbidities strengthen the clinical case for treatment. Patients with prediabetes, sleep apnea, nonalcoholic fatty liver disease, or obesity-related knee pain often qualify at lower BMI cutoffs because semaglutide addresses both weight and metabolic dysfunction. PlexusDx evaluates the full health picture—not just a number on a scale—to recommend compounded semaglutide when clinical need is clear.

Why Many Patients Choose Compounded Semaglutide Over Wegovy

Compounded semaglutide from licensed 503A pharmacies offers the same active ingredient as Wegovy at a lower cost and without insurance dependency. PlexusDx compounded semaglutide injections start at $189/mo (or $149/mo on the 6-month plan) across all 50 states, with no membership fees or insurance approval delays. Patients avoid the brand-name $1,400+ monthly burden and can begin therapy immediately rather than waiting for supply restocking or prior authorizations.

The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes GLP1R, GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Wegovy or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Alternatives When You Don't Qualify for Wegovy

Not every patient fits Wegovy's strict BMI and comorbidity criteria, yet many still benefit from GLP-1 therapy. PlexusDx offers several pathways: oral semaglutide (starting at $289/mo (or $249/mo on the 6-month plan) for those who prefer tablets), tirzepatide injection or oral (starting at $289/mo (or $249/mo on the 6-month plan))—a dual GIP/GLP-1 receptor agonist showing superior weight loss in trials—or the Microdose GLP-1 Protocol at $129/month for metabolic support and appetite modulation at gentler doses. Lifestyle modifications, behavioral coaching, and combination therapies may also apply.

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Getting Started With PlexusDx If You Qualify

Qualification at PlexusDx begins with a brief online health intake, a consultation with a licensed prescriber, and basic labs if not recently done. Unlike Wegovy's rigid brand criteria, PlexusDx prescribers evaluate the full clinical picture—your weight history, metabolic markers, medications, and goals—to determine the best compounded option. Most patients receive an initial prescription within 24–48 hours. HSA and FSA accounts cover compounded medications, reducing your effective out-of-pocket cost further.

Once approved, your first shipment of compounded semaglutide injection arrives with detailed instructions, syringes, and alcohol pads. PlexusDx provides ongoing prescription refills, dose adjustments, and access to a digital health platform for tracking progress and side effects. If you're unsure whether you qualify or which product fits your situation, PlexusDx's team reviews your medical history at no charge and recommends the most cost-effective, medically sound option.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $189/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What if my BMI is 28 and I don't have a diagnosed weight-related condition—do I qualify for semaglutide?

Standard Wegovy criteria require either a BMI of 30+ or a BMI of 27+ with a documented condition like diabetes or hypertension. At BMI 28 with no comorbidities, you may not qualify for the brand. PlexusDx prescribers can evaluate whether compounded semaglutide is clinically appropriate for your situation, especially if you have prediabetes, metabolic syndrome, or other health factors beyond strict BMI thresholds.

Does semaglutide actually work for weight loss, or is it just marketing?

Semaglutide is backed by robust clinical evidence. The STEP trials showed patients on semaglutide lost 15–18% of body weight over 68 weeks, compared to 2–3% on placebo. It works by mimicking GLP-1, a hormone that regulates appetite and blood sugar, slowing stomach emptying and reducing hunger signals. PlexusDx compounded semaglutide contains the same active ingredient as the brand, with identical efficacy at a lower cost.

How much does PlexusDx compounded semaglutide cost compared to Wegovy?

PlexusDx compounded semaglutide injection starts at $189/mo (or $149/mo on the 6-month plan)—flat pricing regardless of dose escalation. Wegovy typically costs $1,400–$1,500 monthly out-of-pocket and requires insurance or enrollment in copay assistance programs. PlexusDx serves all 50 states with no membership or insurance requirement, and HSA/FSA accounts are accepted, making it significantly more affordable.

Are compounded medications as safe as FDA-approved brand-name drugs?

PlexusDx sources all compounded medications from licensed 503A compounding pharmacies, which follow strict FDA oversight, quality standards, and sterility protocols. While compounded medications are not FDA-approved, they are legally manufactured under the same safety regulations as branded drugs. Your PlexusDx prescription includes the same black-box warnings and monitoring requirements as Wegovy to ensure safe use.

What is the Precision Peptide Genetic Test, and how does it help?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves